Vivos Therapeutics Inc Stock Price, News & Analysis

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on treating obstructive sleep apnea (OSA), has announced two strategic executive appointments to support its expansion plans. Michael E. Bruhn joins as Executive Vice President of Business Operations Integration, while Dr. Terry Jones becomes Senior Vice President of Human Resources.

Bruhn, formerly EVP and COO at the United States Institute of Peace, will focus on expanding Vivos' operations in the Eastern United States and managing acquisitions integration, including the recent Sleep Center of Nevada acquisition. Dr. Jones, with over 20 years of leadership experience across federal agencies and private sector, will lead human resources strategy to support the company's growth phase.

Both executives will report directly to CEO R. Kirk Huntsman as Vivos implements its new business model focused on sleep testing centers and direct patient treatment operations.

Vivos Therapeutics (NASDAQ: VVOS) has achieved a significant milestone as its VidaSleep™ oral appliance received approval from the Centers for Medicare & Medicaid Services (CMS) for treating mild to moderate obstructive sleep apnea (OSA) and snoring in adults.

The VidaSleep™ device, featuring Vivos' patented and FDA-cleared Unilateral Bite Block technology, joins the company's mmRNA® device on the PDAC list of covered oral appliances. This dual-PDAC approval makes Vivos the only company with two Medicare-covered oral appliances, expanding access to millions of Medicare beneficiaries.

With an estimated 80 million Americans affected by OSA and over 80% of cases undiagnosed, Vivos is targeting the $36 billion sleep therapy market. The VidaSleep™ device is designed to offer a cost-effective solution without compromising efficacy, maintaining strong gross margins while expanding accessibility through Medicare and commercial insurance networks.

Vivos Therapeutics (NASDAQ: VVOS) announced the publication of groundbreaking clinical trial results in the European Journal of Pediatrics, demonstrating the effectiveness of their Daytime-Nighttime Appliance (DNA) in treating pediatric obstructive sleep apnea (OSA). The study showed 79% of patients experienced OSA improvement, with 61.7% improving by 50% or more.

The trial results validate Vivos' FDA 510(k) clearance received in September 2024 for treating moderate to severe OSA in children. Notably, 93% of children with severe OSA saw symptoms decrease by at least 50%. The DNA device presents a non-surgical alternative to adenotonsillectomy, which has a 68% symptom relapse rate within three years.

Vivos Therapeutics (NASDAQ: VVOS) has completed the acquisition of The Sleep Center of Nevada (SCN), marking a significant pivot in its business model. The $6M cash and $1.5M stock deal includes potential additional $1.5M in stock based on performance milestones. SCN, Nevada's largest sleep testing center, sees 3,000 new patients monthly and generates high seven-figure annual revenues. The acquisition was financed through an $8.225M secured loan from Streeterville Capital and a $3.755M private placement from New Seneca Partners. This strategic move shifts Vivos from a dental provider network model to directly managing sleep practices, allowing immediate capture of OSA diagnostic revenue and treatment opportunities. SCN's network of seven locations and 50 beds for sleep testing, led by Dr. Prabhu Rachakonda and Dr. Tara Rachakonda, will now offer Vivos' FDA-cleared OSA treatments to patients, with full integration expected over 12-18 months.

Vivos Therapeutics (NASDAQ: VVOS) reported its Q1 2025 financial results, showing mixed performance as the company transitions to a new business model. Total revenue decreased to $3.0 million from $3.4 million in Q1 2024, though product revenue increased 8% year-over-year. The company reported a net loss of $3.9 million, slightly higher than the $3.8 million loss in Q1 2024. Operating expenses decreased 5% to $5.4 million, reflecting cost-cutting measures. Notably, Vivos announced plans to acquire The Sleep Center of Nevada for up to $9 million, marking a strategic shift towards direct patient access. The company sold 3,736 oral appliance arches in Q1 2025, generating approximately $1.8 million in revenue. Implementation of new CPT® medical codes for CARE oral medical devices aims to improve reimbursement processes.

Vivos Therapeutics (NASDAQ: VVOS), a medical device and technology company focused on sleep-related breathing disorders treatments, has scheduled its first quarter 2025 financial results release for May 15, 2025, after market close. The company will host a conference call at 5:00 PM ET on the same day to discuss results and recent developments.

Investors can join via phone at (800) 717-1738 (US) or (646) 307-1865 (International). A replay will be available until May 29, 2025, accessible at (844) 512-2921 (US) or (412) 317-6671 (International) with passcode 1124460. A live webcast will be available on Vivos' website with 30-day replay access.

Vivos Therapeutics (NASDAQ: VVOS) has signed a definitive agreement to acquire The Sleep Center of Nevada (SCN), the largest sleep center operator in Nevada, for up to $9 million. The deal includes $6 million in cash, $1.5 million in Vivos common stock at closing, and potential additional $1.5 million in stock tied to performance milestones.

SCN, founded in 2008, serves approximately 3,000 new patients monthly and has generated high seven-figure annual net revenues. The center operates seven locations with nearly 50 beds for overnight sleep testing. About 90% of SCN patients test positive for OSA, with 95% typically referred for CPAP, traditional oral devices, or surgical options.

The acquisition, expected to close in Q2 or Q3 2025, aligns with Vivos' new marketing and distribution model following its June 2024 alliance with Rebis Health. The company aims to expand its FDA-cleared oral appliance treatments for OSA directly to patients seeking alternatives to CPAP or surgery.

Vivos Therapeutics (NASDAQ: VVOS) reported strong financial results for full year 2024, with revenue increasing 9% to $15.0 million from $13.8 million in 2023. Product revenue grew 26% year-over-year, while operating expenses decreased 21% to $20.2 million.

The company maintained a 60% gross margin, with gross profit reaching $9.0 million. Operating loss decreased significantly by 35% to $11.2 million. Cash position stood at $6.3 million after raising $17.9 million through equity transactions in 2024.

Notable achievements include FDA 510(k) clearance for the DNA appliance to treat moderate to severe OSA in children ages 6-17, complementing their 2023 clearance for adult treatment. Patient treatments increased to 58,000 worldwide, up from 42,000 in 2023. The company implemented a strategic pivot towards contractual, profit-sharing alliances with sleep healthcare providers, starting with Rebis Health Holdings, expecting to increase revenue per case by 4-6 times with 50% contribution margins.

Vivos Therapeutics (NASDAQ: VVOS), a medical device and technology company focused on sleep-related breathing disorders treatments, has scheduled its full year 2024 financial results release for Monday, March 31, 2025, after market close.

The company will host a conference call at 5:00 PM ET on the same day to discuss the results and provide updates on recent milestones. Investors can join via phone at (800) 717-1738 (US) or (646) 307-1865 (International). A replay will be available until April 14, 2025, using passcode 1103883. The webcast can be accessed through Vivos' investor relations website, with a 30-day archive available.